216 related articles for article (PubMed ID: 33269540)
1. Interaction of transcription factor AP-2 gamma with proto-oncogene PELP1 promotes tumorigenesis by enhancing RET signaling.
Liu J; Liu Z; Li M; Tang W; Pratap UP; Luo Y; Altwegg KA; Li X; Zou Y; Zhu H; Sareddy GR; Viswanadhapalli S; Vadlamudi RK
Mol Oncol; 2021 Apr; 15(4):1146-1161. PubMed ID: 33269540
[TBL] [Abstract][Full Text] [Related]
2. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
[TBL] [Abstract][Full Text] [Related]
3. Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor.
Spanheimer PM; Woodfield GW; Cyr AR; Kulak MV; White-Baer LS; Bair TB; Weigel RJ
Ann Surg Oncol; 2013 Jul; 20(7):2204-12. PubMed ID: 22878616
[TBL] [Abstract][Full Text] [Related]
4. PELP1 oncogenic functions involve CARM1 regulation.
Mann M; Cortez V; Vadlamudi R
Carcinogenesis; 2013 Jul; 34(7):1468-75. PubMed ID: 23486015
[TBL] [Abstract][Full Text] [Related]
5. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.
De Andrade JP; Park JM; Gu VW; Woodfield GW; Kulak MV; Lorenzen AW; Wu VT; Van Dorin SE; Spanheimer PM; Weigel RJ
Mol Cancer Ther; 2016 Mar; 15(3):503-11. PubMed ID: 26832794
[TBL] [Abstract][Full Text] [Related]
6. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
[TBL] [Abstract][Full Text] [Related]
7. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Cortez V; Mann M; Tekmal S; Suzuki T; Miyata N; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Vadlamudi RK
Breast Cancer Res; 2012 Jul; 14(4):R108. PubMed ID: 22812534
[TBL] [Abstract][Full Text] [Related]
9. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
Cortez V; Samayoa C; Zamora A; Martinez L; Tekmal RR; Vadlamudi RK
Cancer Res; 2014 Dec; 74(24):7395-405. PubMed ID: 25377474
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cell Phenotypes in ER
Truong TH; Hu H; Temiz NA; Hagen KM; Girard BJ; Brady NJ; Schwertfeger KL; Lange CA; Ostrander JH
Mol Cancer Res; 2018 Apr; 16(4):707-719. PubMed ID: 29348189
[TBL] [Abstract][Full Text] [Related]
12. Significance of ER-Src axis in hormonal therapy resistance.
Vallabhaneni S; Nair BC; Cortez V; Challa R; Chakravarty D; Tekmal RR; Vadlamudi RK
Breast Cancer Res Treat; 2011 Nov; 130(2):377-85. PubMed ID: 21184269
[TBL] [Abstract][Full Text] [Related]
13. Regulation of aromatase induction by nuclear receptor coregulator PELP1.
Vadlamudi RK; Rajhans R; Chakravarty D; Nair BC; Nair SS; Evans DB; Chen S; Tekmal RR
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):211-8. PubMed ID: 19800002
[TBL] [Abstract][Full Text] [Related]
14. Significance of PELP1 in ER-negative breast cancer metastasis.
Roy S; Chakravarty D; Cortez V; De Mukhopadhyay K; Bandyopadhyay A; Ahn JM; Raj GV; Tekmal RR; Sun L; Vadlamudi RK
Mol Cancer Res; 2012 Jan; 10(1):25-33. PubMed ID: 22086908
[TBL] [Abstract][Full Text] [Related]
15. PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Truong TH; Benner EA; Hagen KM; Temiz NA; Kerkvliet CP; Wang Y; Cortes-Sanchez E; Yang CH; Trousdell MC; Pengo T; Guillen KP; Welm BE; Dos Santos CO; Telang S; Lange CA; Ostrander JH
Oncogene; 2021 Jun; 40(25):4384-4397. PubMed ID: 34103681
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.
Kulak MV; Cyr AR; Woodfield GW; Bogachek M; Spanheimer PM; Li T; Price DH; Domann FE; Weigel RJ
Oncogene; 2013 Aug; 32(34):4043-51. PubMed ID: 22964634
[TBL] [Abstract][Full Text] [Related]
17. Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.
Nagpal JK; Nair S; Chakravarty D; Rajhans R; Pothana S; Brann DW; Tekmal RR; Vadlamudi RK
Mol Cancer Res; 2008 May; 6(5):851-61. PubMed ID: 18505929
[TBL] [Abstract][Full Text] [Related]
18. PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.
Luo Y; Li M; Pratap UP; Viswanadhapalli S; Liu J; Venkata PP; Altwegg KA; Palacios BE; Li X; Chen Y; Rao MK; Brenner AJ; Sareddy GR; Vadlamudi RK
Mol Carcinog; 2020 Mar; 59(3):281-292. PubMed ID: 31872914
[TBL] [Abstract][Full Text] [Related]
19. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
20. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
Roy SS; Gonugunta VK; Bandyopadhyay A; Rao MK; Goodall GJ; Sun LZ; Tekmal RR; Vadlamudi RK
Oncogene; 2014 Jul; 33(28):3707-16. PubMed ID: 23975430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
